Biotech · Public company · US
Amneal Pharmaceuticals, Inc.
Ticker AMRX · SEC CIK 0001723128
Track this companyFree. Adds Amneal Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials85 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline10
- Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Phase 3 · Glaucoma, Open-AngleClinicalTrials.gov · fetched Nov 12, 2026
- Test - Bimatoprost 0.01% Ophthalmic SolutionPhase 3 · Glaucoma, Open-AngleClinicalTrials.gov · fetched Nov 12, 2026
- Testosterone cypionate 100 mgPhase 3 · Male HypogonadismClinicalTrials.gov · fetched Nov 12, 2026
- Testosterone cypionate 50 mgPhase 3 · Male HypogonadismClinicalTrials.gov · fetched Nov 12, 2026
- Testosterone Cypionate 75 mgPhase 3 · Male HypogonadismClinicalTrials.gov · fetched Nov 12, 2026
- Bimatoprost Ophthalmic Solution, 0.01%Phase 1 · Open-angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- KSHN001126 150mgPhase 1 · Healthy Postmenopausal WomenClinicalTrials.gov · fetched Nov 12, 2026
- KSHN001126 300mgPhase 1 · Healthy Postmenopausal WomenClinicalTrials.gov · fetched Nov 12, 2026
- KSHN001126 600mgPhase 1 · Healthy Postmenopausal WomenClinicalTrials.gov · fetched Nov 12, 2026
- LUMIGAN® (bimatoprost ophthalmic solution) 0.01%Phase 1 · Open-angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With HypogonadismPHASE3 · RECRUITING · started Sep 28, 2026ClinicalTrials.gov NCT07898072 · fetched Nov 12, 2026
- BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's DiseasePHASE4 · RECRUITING · started Jul 24, 2025ClinicalTrials.gov NCT07138560 · fetched Nov 12, 2026
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's DiseasePHASE4 · RECRUITING · started Feb 12, 2025ClinicalTrials.gov NCT06765668 · fetched Nov 12, 2026
- SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal FemalesPHASE1 · COMPLETED · started Jun 3, 2024ClinicalTrials.gov NCT06467201 · fetched Nov 12, 2026
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesPHASE1 · UNKNOWN · started Apr 1, 2024ClinicalTrials.gov NCT06267274 · fetched Nov 12, 2026
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.PHASE3 · RECRUITING · started Jun 29, 2022ClinicalTrials.gov NCT05401357 · fetched Nov 12, 2026
- The Mycophenolate Pregnancy RegistryCOMPLETED · started Nov 20, 2012ClinicalTrials.gov NCT01733082 · fetched Nov 12, 2026
- Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.RECRUITING · started Jan 1, 1989ClinicalTrials.gov NCT00404989 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Oct 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 22, 2026 · fetched Nov 12, 2026